Teva Pharma Industries Ltd ADR (TEVA)vscbdMD Inc (YCBD)
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
YCBD
cbdMD Inc
$0.77
+1.06%
HEALTHCARE · Cap: $6.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 90607% more annual revenue ($17.26B vs $19.03M). TEVA leads profitability with a 8.2% profit margin vs -8.0%. YCBD trades at a lower P/E of 1.4x. TEVA earns a higher WallStSmart Score of 73/100 (B).
TEVA
Strong Buy73
out of 100
Grade: B
YCBD
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Margin of Safety
+78.3%
Fair Value
$3.47
Current Price
$0.77
$2.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -33.1% — below average capital efficiency
Revenue declined 11.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bull Case : YCBD
The strongest argument for YCBD centers on P/E Ratio, Price/Book.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Bear Case : YCBD
The primary concerns for YCBD are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
TEVA profiles as a value stock while YCBD is a turnaround play — different risk/reward profiles.
YCBD carries more volatility with a beta of 2.21 — expect wider price swings.
TEVA is growing revenue faster at 11.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 31/100) and 11.4% revenue growth. YCBD offers better value entry with a 78.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
cbdMD Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company is headquartered in Charlotte, North Carolina.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?